Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 1066-1073

  Maurer, Matthew J ^a   Ghesquières, Hervé ^a,b,c   Jais, Jean Philippe ^d   Witzig, Thomas E ^a   Haioun, Corinne ^f   Thompson, Carrie A ^a   Delarue, Richard ^d   Micallef, Ivana N ^a   Peyrade, Fréd́eric ^g   Macon, William R ^a   Molina, Thierry Jo ^e   Ketterer, Nicolas ^k   Syrbu, Sergei I ^l   Fitoussi, Olivier ^h   Kurtin, Paul J ^a   Allmer, Cristine ^a   Nicolas Virelizier, Emmanuelle ^b   Slager, Susan L ^a   Habermann, Thomas M ^a   Link, Brian K ^l   Salles, Gilles ^c,i   Tilly, Hervé ^j   Cerhan, James R ^a   more..

^a MAYO CLINIC   (United States)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g CENTRE ANTOINE LACASSAGNE   (France)

^h Polyclinique Bordeaux Nord   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j CENTRE HENRI BECQUEREL   (France)

^k Children's Hospital Lausanne   (Switzerland)

^l UNIVERSITY OF IOWA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINDESINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; COUNSELING; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FRANCE; HOSPITAL PATIENT; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT OUTCOME; ADOLESCENT; CASE CONTROL STUDY; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECURRENCE; TIME FACTORS; YOUNG ADULT;

EID: 84901700388     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.51.5866     Document Type: Article

References (27)

1. Morton LM, Wang SS, Devesa SS, et al: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265-276, 2006 (Pubitemid 43053551)
2. Tilly H, Vitolo U, Walewski J, et al: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 23:vii78-vii82, 2012
3. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
4. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
5. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5033, 2005 (Pubitemid 46224009)
6. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
7. Friedberg JW: Relapsed/Refractory Diffuse Large B-Cell Lymphoma. ASH Education Book 2011:498-505, 2011
8. Coiffier B, Thieblemont C, Van Den Neste E, et al: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116:2040-2045, 2010
9. Larouche JF, Berger F, Chassagne-Clément C, et al: Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: Clinical characteristics and outcome. J Clin Oncol 28:2094-2100, 2010
10. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184-4190, 2010
11. Nowakowski GS, Maurer MJ, Habermann TM, et al: Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 28:412-417, 2010
12. Drake MT, Maurer MJ, Link BK, et al: Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 28:4191-4198, 2010
13. Maurer MJ, Micallef IN, Cerhan JR, et al: Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol 29:1620-1626, 2011
14. Micallef IN, Maurer MJ, Wiseman GA, et al: Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118:4053-4061, 2011
15. Récher C, Coiffier B, Haioun C, et al: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet 378:1858-1867, 2011
16. Fitoussi O, Belhadj K, Mounier N, et al: Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica 96:1136-1143, 2011
17. Peyrade F, Jardin F, Thieblemont C, et al: Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460-468, 2011
18. Ketterer N, Coiffier B, Thieblemont C, et al: Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol 24:1032-1037, 2013
19. Delarue R, Tilly H, Mounier N, et al: Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): A randomised phase 3 trial. Lancet Oncol 14:525-533, 2013
20. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
21. Therneau TM, Lumley T: Survival analysis, including penalised likelihood (R package version 2.36-10). http://CRAN.R-project.org/package=survival
22. Jais J-P, Varet H: Survexp.fr: Relative survival, AER and SMR based on French death rates (R package version 1.0). http://CRAN.R-project.org/package= survexp.fr
23. Therneau T, Sicks J, Bergstralh E, et al: Expected survival based on hazard rates. Technical Report No. 52. Rochester, MN, Mayo Clinic, March 1994
24. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer-Verlag, 2000
25. Verheul HA, Dekker E, Bossuyt P, et al: Background mortality in clinical survival studies. Lancet 341:872-875, 1993 (Pubitemid 23094522)
26. Breslow NE, Lubin JH, Marek P, et al: Multiplicative models and cohort analysis. J Am Stat Assoc 78:1-12, 1983
27. Link BK, Brooks J, Wright K, et al: Diffuse large B-cell lymphoma in the elderly: Diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 52:994-1002, 2011